Verma S, Mazer CD, Yan AT, et al. - Between November 2016 and April 2018, researchers enrolled 97 individuals aged ≥ 40 years and ≤ 80 years with glycated hemoglobin 6.5 to 10.0%, known coronary artery disease (CAD), and estimated glomerular filtration rate (eGFR) ≥ 60mL/min/1.73m² in order to ascertain whether empagliflozin causes a reduction in left ventricular (LV) mass in people with type 2 diabetes (T2D) and CAD. A total of 90 participants had evaluable imaging at follow-up. For that allocated empagliflozin and placebo, mean LV mass indexed (LVMi) regression over 6 months was 2.6 g/m² and 0.01 g/m², respectively. Significant reductions in overall ambulatory systolic blood pressure and diastolic blood pressure, as well as a rise of hematocrit in the empagliflozin-allocated group was noted. Thus, among people with T2D and CAD, sodium-glucose co-transporter 2 inhibition with empagliflozin was related to a notable decrease in LVMi following 6 months, which may account, in part, for the advantageous cardiovascular outcomes seen in the EMPA-REG OUTCOME trial.